High-titer GAD65 antibodies in serum and CSF are significant biomarkers for autoimmune neurological diseases, including stiff person syndrome, cerebellar ataxia, limbic encephalitis (LE), and AAE. This evidence concerns the gene GAD2 and acquired angioedema.